Notably, the combination of IFN-DC-based vaccination plus lenalidomide exhibited an additive therapeutic effect, resulting far more effective than either single treatment, leading to a massive regression of established tumors and delayed tumor regrowth upon treatment discontinuation. Here, IFNA1 is linked to neoplasm.